Abstract.
The spondyloarthropathies (SpA) are a related group of disorders, characterized primarily by spondylitis, pauci-articular arthritis and enthesitis. The presence of subclinical gut inflammation in patients with SpA ranges from 25 to 75%, depending upon the type of SpA. Several data suggest that the association between gut inflammation and synovitis reflects an etiopathogenetic relationship, and that strategies which interfere with the gut inflammation may also modulate the synovitis. Here we review some standard as well as experimental drugs used in the treatment of patients with inflammatory bowel disease and discuss what is known about their effect on SpA-related locomotor manifestations. For the more experimental drugs, such as cytokines, anti-cytokines and anti-adhesion compounds, clinical trials in patients with SpA are still very scarce.
Article PDF
Similar content being viewed by others
Avoid common mistakes on your manuscript.
Author information
Authors and Affiliations
Additional information
Received 4 February 1999; returned for revision 27 April 1999; accepted by M. J. Parnham 6 October 1999
Rights and permissions
About this article
Cite this article
De Keyser, F., Van Damme, N., De Vos, M. et al. Opportunities for immune modulation in the spondyloarthropathies with special reference to gut inflammation. Inflamm. res. 49, 47–54 (2000). https://doi.org/10.1007/s000110050558
Issue Date:
DOI: https://doi.org/10.1007/s000110050558